Invesco
TRVI icon

Invesco’s Trevi Therapeutics TRVI Stock Holding History

Invesco’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.81M Sell
311,749
-41,235
-12% -$600K ﹤0.01% 2166
2026
Q1 		$4.21M Sell
352,984
-145,942
-29% -$1.63M ﹤0.01% 2264
2025
Q4 		$6.25M Buy
498,926
+15,856
+3% +$183K ﹤0.01% 2132
2025
Q3 		$4.42M Buy
483,070
+160,731
+50% +$1.21M ﹤0.01% 2284
2025
Q2 		$1.76M Sell
322,339
-530,646
-62% -$3.3M ﹤0.01% 2617
2025
Q1 		$5.37M Buy
852,985
+829,364
+3,511% +$3.96M ﹤0.01% 2115
2024
Q4 		$97.3K Buy
23,621
+4,133
+21% +$13.2K ﹤0.01% 3628
2024
Q3 		$65.1K Sell
19,488
-235
-1% -$699 ﹤0.01% 3660
2024
Q2 		$58.8K Sell
19,723
-165
-0.8% -$458 ﹤0.01% 3803
2024
Q1 		$68.6K Hold
19,888
– – ﹤0.01% 3779
2023
Q4 		$26.6K Buy
19,888
+3,842
+24% +$5.82K ﹤0.01% 3788
2023
Q3 		$35K Hold
16,046
– – ﹤0.01% 3821
2023
Q2 		$38.4K Buy
+16,046
New +$40.4K ﹤0.01% 3833

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Invesco's TRVI Position: Q2 2026 in Review

Invesco reduced its Trevi Therapeutics (TRVI) stake by 12% in Q2 2026, selling an estimated $600K and leaving 311,749 shares worth $5.81M. The position accounts for ﹤0.01% of the portfolio, ranked #2166.

Invesco first reported a position in TRVI in Q2 2023 and has held it in 13 quarters since. The position peaked at $6.25M in Q4 2025. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Invesco held 311,749 shares of Trevi Therapeutics worth $5.81M as of Q2 2026.
  • Invesco sold 41,235 Trevi Therapeutics shares in Q2 2026, an estimated $600K.
  • Trevi Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2166 holding.
  • Invesco first reported a position in Trevi Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • Invesco's Trevi Therapeutics position peaked at $6.25M in Q4 2025.
  • 219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.